SEARCH:      Monitor Keywords |  Custom RSS

Organic compounds -- part of the class 532-570 series October categorized by USPTO classification 10/11

20110263893 - Products, process for producing them, and their use: P

20110263894 - Method for compressing gases containing hydrogen sulfide: a process for producing sulfur compounds, selected from the group consisting of alkylmercaptans, dialkyl disulfides and alkanesulfonic acids, which comprises the conversion of hydrogen-sulfide-comprising gas streams, wherein the hydrogen-sulfide-comprising gas streams are compressed according to the process comprising steps i) and ii); and also the use of a mixture comprising... Agent: Basf Se

20110263895 - Recovery of acetic acid from wood extracts: In a process for recovering acetic acid from a wood extract, an aqueous wood extract is provided that contains acetic acid and dissolved hemicellulose containing uronic acid. A water insoluble solvent containing an extractant for the acetic acid is also provided. In a preferred embodiment, the solvent is undecane and... Agent:

20110263896 - Process for enantioseparation of chiral systems with compound formation using two subsequent crystallization steps: Method for enantioseparation of a chiral system with compound formation comprising a pair of enantiomers. The method comprises the steps of: placing the chiral system to be processed, which is optically enriched by a target enantiomer, in the 3-phase region of the ternary phase diagram of chiral compound forming systems... Agent:

20110263897 - preparation method of high-purity l-carnitine: The present invention relate to a preparation method of high-purity L-carnitine which belongs to an important technique of quality control in different steps of chiral medicine production. The method comprises the following steps of: monitoring the content of the L-isomer impurity in chiral material S-epichlorohydrin by gas chromatography and chiral... Agent:

20110257429 - Method for producing a free acid from the salt thereof: The invention relates to an improved method for releasing an organic acid, preferably a carbon, sulfone or phosphone acid, particularly an alpha or beta hydroxycarbon acid, from the ammonia salt thereof by releasing and removing ammoniac and simultaneous extraction of the released acid, having an amine as a suitable extraction... Agent: Evonik Degussa Gmbh

20110257430 - Novel cocrystallization: The present disclosure relates to novel cocrystals and novel methods for cocrystallization. In particular, the disclosure includes cocrystals comprising a salt of an active agent, such as a chloride salt of an active pharmaceutical ingredient. The present disclosure also relates to methods of preparing cocrystals and methods for screening for... Agent: Aptuit (kansas City), LLC

20110257431 - Process for producing side product-free aminocarboxylates: The present invention relates to a process for preparing aminocarboxylates, proceeding from amines, by employing a reaction sequence composed of ethoxylation to amino alcohols and subsequent oxidative dehydrogenation to the corresponding aminocarboxylates, especially the alkali metal or alkaline earth metal salts of the complexing agents MGDA (methylglycinediacetic acid), EDTA (ethylenediaminetetra-acetic... Agent: Basf Se

20110257432 - Metformin-cysteine prodrug: A metformin-cysteine prodrug. It is believed that the prodrug of the present invention will transport in the LAT1 and LAT2 transporter system. Because the LAT1 and LAT2 transporters are important and effective transporters of amino acids in both the small intestine and colon, it is believed that the LAT-transportable prodrugs... Agent:

20110257433 - Liquids: The present invention relates to an ionic liquid comprising an anion and a cation, wherein the cation is a primary, secondary or tertiary ammonium ion containing a protonated nitrogen atom.... Agent: The University Of York

20110257434 - Perturbed membrane-binding compounds and methods of using the same: The invention relates to compounds that selectively bind to cells undergoing perturbations and alterations of their normal plasma membrane organization, i.e., cells undergoing cell death, apoptotic cells or activated platelets. The invention further provides methods for utilizing the compounds in medical practice, for diagnostic and therapeutic purposes.... Agent:

20110251426 - Screening for solid forms by ultrasound crystallization and cocrystallization using ultrasound: The present disclosure relates to crystallizing a chemical substance(s) using ultrasound. Methods are provided for screening a chemical substance according to its solid forms by using ultrasound to generate new or unusual solid forms. Methods are also provided for crystallizing a chemical substance by novel techniques that include sonication. The... Agent: S.s.c.i., Inc.

20110251427 - Polyfluoralkane carboxylic acid (or its salt) and process for producing the same: , where its carboxylic acid salt can be formed as an alkali metal salt, or a NH4 salt. The polyfluoroalkane carboxylic acid (or its salt) can act as a surfactant having distinguished monomer emulsificability and latex stability when used as an emulsifying agent or as a dispersing agent for polymerization... Agent: Nippon Mektron, Limited

20110251428 - Use of chlorine guanabenz derivatives for treating prion-based diseases: The invention relates to chlorine Guanabenz derivatives for treating prion-based diseases. More specifically, it relates to the use of the molecule of formula (I) wherein R═H or Cl and the phenyl group is at least substituted twice, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for... Agent:

20110251429 - Chlorothioformate manufacturing method: The present invention relates to a process for producing chlorothioformate comprising reacting an alkenyl mercaptan with phosgene in a reactor in the presence of a carboxylic acid amide in an organic solvent, characterized in that the carboxylic acid amide is preliminary charged to the reactor in an amount of 10... Agent: Sumitomo Chemical Company, Limited

20110245533 - Nanoparticle including multi-functional ligand and method: A nanoparticle including an inorganic core comprising at least one metal and/or at least one semi-conductor compound comprising at least one metal includes a coating or shell disposed over at least a portion of a surface of the core. The coating can include one or more layers. Each layer of... Agent:

20110245534 - Novel polymorphic form of chdmapp, method of preparation thereof, and pharmaceutical composition comprising same: The present invention relates to novel polymorphs of (2E)-1-hydroxy-2-methylpent-2-enyl-pyrophosphonate disodium (CHDMAPP-Na2), to the process for preparing them and to the pharmaceutical compositions containing them.... Agent: Innate Pharma

20110245535 - Multi-metal oxide catalyst and method for producing (meth)acrylic acid by using the same: The present invention provides a Mo—Bi—Nb based composite metal oxide (with the proviso that Te is not included); a method for producing (meth)acrylic acid from at least one reactant selected from the group consisting of propylene, propane, isobutylene, t-butyl alcohol and methyl-t-butyl ether, in which a Mo—Bi—Nb based composite metal... Agent:

20110245536 - Process for preparing pregabalin: Disclosed herein is an improved, commercially viable and industrially advantageous process for the preparation of pregabalin in high yield and purity. The present invention also provides a process for the purification of (S)-pregabalin.... Agent: Actavis Group Ptc Ehf

20110245537 - L-carnitine calcium fumarate, preparation method and application for the same: L-carnitine calcium fumarate and its preparation and applications are disclosed in the present invention. Having good water solubility as well as better and stronger nutritious and treating functions than the corresponding inner salts, the L-carnitine calcium fumarate as proposed having the advantages of being non-hygroscopic, stable in chemical property, and... Agent: Liaoning Konepnutra Co., Ltd